Abstract 149P
Background
Diffuse large B cell lymphoma (DLBCL) is the most common type of NHL, accounting for 30–40% of diagnoses of them worldwide. MicroRNAs are small non-coding RNAs involved in many important biological processes, and in neoplastic diseases so, the roles of microRNAs have been investigated in various types of solid and hematologic tumors, including DLBCL.we aimed to studySerum mi-RNA -155 and mi-RNA- 92a in patients with diffuse large B cell lymphoma.
Methods
Fifty DLBCL patients and fifty age and gender matched healthy controls. Serum mi-RNA -155 and mi-RNA- 92a expression levels were performed by real time q PCR technique. Different patients clinicopathological data and disease outcome are correlated with mi-RNA -155 and mi-RNA- 92a levels.
Results
There was significant statistical increase of the expression of serum miR-155 and significant statistical decrease in the expression of serum miR-92a in patients compared to control group, ( in both p value< 0.001). Regarding survival of DLBCL, patients with low miR-155 expression have better Overall Survival and progression free survival than with high miR-155 expression but the difference was statistically nonsignificantat a cutoff point of 1.9 . Overall Survival and progressionfree survival is better in patients with high serum miR-92a expressionthan in patients with low serum miR-92a expressionat a cutoff point of 0.49 but the difference was statistically non-significant.
Conclusions
It could be concluded thatserum miR -155 might be used as diagnostic and prognostic marker of DLBCL at a cutoff points of1.9and15.54 respectively and serum miR-92a could be used as diagnostic and prognostic marker of DLBCL at a cutoff points of 0.94 and 0.14 respectively.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Menoufia university.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.